Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused

Inhibikase Therapeutics, Inc.

Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.
No improvement on primary efficacy measure MDS-UPDRS Parts 2+3 at any dose vs placebo.
Secondary signals: Part 2 improved -1.41 at 100 mg (p=0.036); Schwab & England +4% at 50 mg (p=0.0004).
Skin biopsy analysis suggests treatment-dependent reduction in neuronal alpha-synuclein deposition.
Company pausing risvodetinib to focus resources on IkT-001Pro for PAH; evaluating strategic options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.